vibegron

Urovant's lead drug disappoints in mid-stage study as first big FDA decision looms
Endpoints
Wed, 11/25/20 - 10:29 am
Urovant
vibegron
IBS-d
clinical trials
As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma
Fierce Biotech
Fri, 11/13/20 - 12:50 pm
Urovant
Roivant
FDA
vibegron
overactive bladder
FDA sets Dec. PDUFA date for Urovant rival to Astellas drug
Fierce Biotech
Fri, 03/6/20 - 10:42 am
Urovant Sciences
overactive bladder
vibegron
FDA
Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival
Endpoints
Tue, 03/19/19 - 10:30 am
Axovant
Alzheimer's disease
Roivant
Vivek Ramaswamy
Urovant
vibegron
urinary incontinence
Urovant's overactive bladder drug scores in mid-stage trial
Endpoints
Thu, 11/1/18 - 11:32 am
Urovant Sciences
overactive bladder
clinical trials
vibegron